David Anthony Clump II, MD, PhD

  • Assistant Professor, Radiation Oncology
  • Physician, UPMC Shadyside

I am physician-scientist in the Department of Radiation Oncology at UPMC and the University of Pittsburgh Cancer Institute, where my clinical practice is devoted to the treatment of patients with cancers of the upper aerodigestive tract and well as utilization of stereotactic radiotherapy (SRS/SBRT) for primary and recurrent disease. While both conventional as well as targeted radiotherapy are integrated into the curative management of many of these patients, a complete understanding of the DNA damage response following these treatments is not fully elicited. Specifically, an increased understanding of the DNA damage response especially as it relates to the immune response affords a novel opportunity to maximize the therapeutic ratio by augmenting the subsequent signaling cascade. Our translational efforts have identified the importance of a loading dose of anti-PD1 therapy prior to initiating radiation therapy. Additional efforts have sought the characterization of the ATM phosphorylation cascade in relation to the treatment response as well as the toxicity profile in patients receiving radiotherapy. These and additional preliminary data were generated with successful grant support from the Head and Neck SPORE career development fund as well as the Center for Medical Countermeasures Against Radiation (CMCR) program. Current laboratory support is provided by the Lung SPORE program and Astra Zeneca.

Representative Publications

Horne ZD, Clump DA, Vargo JA, Shah S, Beriwal S, Burton SA, Quinn AE, Schuchert MJ, Landreneau RJ, Christie NA, Luketich JD, Heron DE. Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Radiat Oncol. 2014

Davis KS, Vargo JA, Ferris RL, Burton SA, Ohr JP, Clump DA, Heron DE.  Stereotactic body radiotherapy for recurrent oropharyngeal cancer - influence of HPV status and smoking history.  Oral Oncol. 2014

Vargo JA, Ferris RL, Clump DA, Heron DE.  Stereotactic Body Radiotherapy as Primary Treatment for Patients with Medically Inoperable Head and Neck Cancer.  Frontiers in Radiation Oncology. 2014

Vargo JA, Ferris RL, Ohr J, Clump DA, Davis KS, Duvvuri, U, Kim S, Johnston JT, Bauman JE, Gibson MK, Branstetter BF, Heron DE.  A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.  Int J Radiat Oncol Biol Phys. 2015.

Xu KM, Quan K, Clump DA, Ferris RL, Heron DE. Stereotactic ablative radiosurgery for locally advanced or recurrent skull base malignancies with prior external beam radiation therapy.  Front Oncol. 2015.

Holt DE, Gill BS, Clump DA, Leeman JE, Burton SA, Amankulor NM, Engh JA, Heron DE.  Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis. Front Oncol. 2015. 

Clump DA, Bauman JE, Ferris RL.  Cancer of the Oropharynx. Surg Oncol Clin N Am. 2015.

Gill BS, Clump DA, Burton SA, Christie NA, Schuchert MJ and Heron DE. Salvage stereotactic body radiotherapy for locally recurrent non-small cell lung cancer after sublobar resection and I-125 vicryl mesh brachytherapy.  Front Oncol. 2015.  

Pennathur A, Luketich JD, Heron DE, Schuchert MJ, Bianco V, Clump D, Burton S, Abbas G, Gooding WE, Ozhasogul C, Landreneau RJ, Christie NA. Stereotactic Radiosurgy/Steretactic Body Radiotherapy for Recurrent Lung Neoplasm: An Analysis of Outcomes in 100 Patients. Ann Thor Surg 2015. 

Quan K, Xu KM, Lalonde R, Horne ZD, Bernard MD, McCoy C, Clump DA, Burton SA, Heron DE. Treatment Plan Technique and Quality for Single-Isocenter Stereotactic Ablative Radiotherapy for Multiple Lung Lesions with Volmetric-Modulated Arc Therapy or Intensity-Modulated Radiosurgery. Front Oncol. 2015. 

Davis KS, Lim CM, Clump DA, Heron DE, Ohr JP, Kim S, Duvvuri U, Johnson JT, Ferris RL. Tumor Volume as a Predictor of Survival in Human Papillomavirus-Positive Oropharyngeal Cancer. Head Neck 2015.

Newman WC, Williams L, Duvvuri U, Clump DA, Amankular N. Hyalinizing Clear Cell Carcinoma with Biopsy Proven Spinal Metastases: Case Report and Review of the Literature. World Neurosurg. 2016.

Glaser SM, Mandish SF, Gill BS, Balasubramani GK, Clump DA, Beriwal S. Anaplastic thyroid cancer: Prognostic factors, patters of care, and overall survival. Head Neck. 2016. 

Quan K, Xu KM, Zhang Y, Clump DA, Flickinger JC, Lalonde R, Burton SA, Heron DE. Toxicities following Stereotactic Ablative Radiotherapy of Locally-Recurrent and Previously-Irradiated Head and Neck Squamous Cell Carcinoma.  Seminars in Radiation Oncology.  2016. 

Horne ZD, Glaser SM, Vargo JA, Ferris RL, Balasubramani GK, Clump DA, Heron DE, Beriwal S. Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. Cancer 2016.

Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulo M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL. Phase II randomized trial of radiation therapy, cetuximab and pemetrexed with or without bevacizumab in patients with locoregionally-advanced head and neck cancer. Ann Oncol. 2016.

Ling DC, Vargo JA, Ferris RL, Ohr J, Clump DA, Yau Wy, Durvvuri D, Kim S, Johnson JT, Bauman JE, Branstetter BF, Heron DE. Risk of Severe Toxicity According to Site of Recurrence in Patients Treated with Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016.

Albergotti WG, Davis KS, Abberbock, S, Bauman JE, Ohr J, Clump DA, Heron DE, Duvvuri U, Kim S, Johnson JT, Ferris RL. Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma.  Oral Oncol. 2016. 

Research Grants

Faculty Support on Research grants is 8 percent.

Ongoing Research Support:

Lung SPORE Project 4

Preclinical Assessment of Bioavailable and Orally Active ATR Kinase Inhibitors for the Treatment of Lung Cancer Bakkenist and Clump, co-PIs

UPMC Cancer Centers (Stanley Marks Foundation)

ATM for the Pharmacodynamic Determination of 223Radium Dichloride in Metastatic Bone Disease  

AstraZeneca

AZD6738/ATRi and AZD0156/ATMi as radiosensitizers: 223Ra (Xofigo) combinations Bakkenist PI, Clump co-I 

UPP

ATR kinase inhibitors for the treatment of lung cancer Bakkenist, PI, Clump, co-I

NIAID/NIH

Functions of ATR in radiation mitigation Bakkenist PI, Clump co-I

AstraZeneca

DNA Damage Signaling to Immune Checkpoints Bakkenist PI, Clump co-I 

AstraZeneca

Treatment response to radiation and DNA repair inhibitor combinations in vivo Bakkenist PI, Clump co-I

Henry M. Jackson Foundation for the Advancement of Military Medicine DoD

Preclinical Assessment of a Bioavailable and Orally Active ATR Kinase Inhibitor for the Treatment of Ovarian Cancer Bakkenist, PI, Clump, co-I

 

Bristol Myers Squibb

LLLT for radiation and cetuximab induced dermatitis

Completed Research Support

Head and Neck SPORE Career Development Award

CMCR Pilot Project Co-PI: ATM as a biomarker for radiation exposure

Shadyside Foundation- LLLT for radiation induced mucositis

CMCR Pilot Project PI: ATM as a biomarker for radiation exposure